Dividends & Buybacks ·
Scinai Immunotherapeutics Ltd. announced an effective change to its American Depositary Share (ADS) ratio on August…
SCNIScinai Immunotherapeutics Ltd.
Scinai Immunotherapeutics Ltd. announced an effective change to its American Depositary Share (ADS) ratio on August 21, 2026, adjusting the conversion rate from one ADS representing 4,000 ordinary shares to one ADS representing 40,000 ordinary shares. This adjustment functions as a one-for-ten reverse split of the ADSs and is intended to increase the per-ADS trading price to regain compliance with Nasdaq Listing Rule 5550(a)(2), which mandates a minimum bid price of $1.00 per ADS. Fractional entitlements will be aggregated and sold by the depositary bank, with net proceeds distributed to holders. The company operates in the biotechnology industry, focusing on immunotherapy treatments for cancer.